In short
Clinical trials are investigating Acou085 in people with testicular cancer who are receiving cisplatin. The main goal is to see whether it can help prevent hearing loss and to check safety, tolerability, and early signs of benefit.
Key points
- Clinical trials of Acou085 are studying whether it can help prevent hearing loss in people with testicular cancer who receive cisplatin chemotherapy. The available trial is a Phase 2 study and was completed with 40 participants. It compared Acou085 with a placebo and looked at hearing changes over time, especially at high and extended high sound frequencies. The main goal was to see whether fewer patients developed a meaningful difference in hearing between ears after treatment. The trial also focused on safety and tolerability. This is research in a specific cancer treatment setting, not a general study of all hearing loss.
Trial overview
The available study of Acou085 was a clinical trial in people with testicular cancer who were receiving cisplatin chemotherapy. The study asked whether Acou085 could help prevent hearing loss caused by cisplatin, which is known in the trial data as ototoxic damage, meaning ear damage from a medicine.
This was an interventional study, which means the researchers gave a treatment and then measured its effects. The trial also looked at safety, tolerability, and early signs of benefit.
Who was studied
The trial targeted patients with testicular cancer who were receiving cisplatin chemotherapy. The data do not list all detailed eligibility rules, but the study population was clearly focused on this cancer treatment setting.
In simple terms, the study group was made up of people at risk of hearing loss because of their cancer treatment, not people with hearing loss from any cause.
What was tested
The trial compared Acou085 with a placebo, which is a look-alike treatment with no active ingredient. The placebo was designed to match the study drug in appearance and size.
Acou085 was given as a transtympanic injection, meaning it was injected through the eardrum into the middle ear area. The trial data do not provide a broader drug description, so the focus here is only on how it was studied in this trial.
What was measured
The main outcome was the proportion of patients who had a difference of at least 10 decibels between both ears in at least two hearing frequencies. A decibel is a unit used to measure sound level, and a difference of 10 decibels can show a meaningful change in hearing.
The hearing test used was pure tone audiometry, or PTA, which checks hearing at different pitches. The trial focused on high frequencies and extended high frequencies, including 4, 6, 8, 10, 12, 14, and 16 kHz, because these can be affected early by hearing damage.
Researchers compared hearing at baseline, before cisplatin started, with hearing at the end of the third chemotherapy cycle on Day 64. This helped them see whether hearing changed during treatment.
Trial phase and status
The study was a Phase 2 trial. Phase 2 studies are used to look more closely at whether a treatment may help, while still checking safety and tolerability.
The trial status is completed, and the enrollment was 40 participants. This means the study was finished and the planned measurements were collected.
What these results mean for patients
This research is about protecting hearing during a cancer treatment that can cause ear damage. The study was designed to see whether Acou085 could reduce hearing changes in a very specific group: people with testicular cancer receiving cisplatin.
The trial does not study all forms of hearing loss, and it does not describe Acou085 as a general treatment for hearing problems. Instead, it focuses on one prevention question in one treatment setting, using hearing tests as the main way to judge the effect.